Osteoarthritis (OA)

Musculoskeletal·MeSH: Osteoarthritis

Prevalence

8237.4 / 100K

Incidence

622.3 / 100K/yr

8 drugs in development·8 companies·1 clinical trial

Drug Pipeline by Phase

Approved(6)

Drug	Company
celecoxib	Aptinyx Inc. (APTX)
celecoxib	Zomedica Corp. (ZOMDF)
celecoxib	ACADIA PHARMACEUTICALS INC (ACAD)
celecoxib	Miromatrix Medical Inc. (MIRO)
celecoxib	AlphaTON Capital Corp (ATON)
meloxicam	Mylan II B.V. (MYL)

Phase 3(1)

Drug	Company
Apitox (Apitoxin in South Korea)	Apimeds Pharmaceuticals US, Inc. (APUS)

Phase 2(1)

Drug	Company
enekinragene inzadenovec	ACURA PHARMACEUTICALS, INC (ACUR)

BioSniper tracks 8 drugs in development for Osteoarthritis (OA) across 8 companies.

There are 1 clinical trial targeting Osteoarthritis (OA) tracked by BioSniper.

The estimated prevalence of Osteoarthritis (OA) is approximately 8237.4 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.